Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Achieve Life Sciences, Inc.

NASDAQ: QUIT · Life Sciences · 3 alerts · CIK 949858

Share price
$6.06Close, Nov 16
Market cap
$667M
Shares outstanding
110.03MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Achieve Life Sciences, Inc. filings on SEC EDGAR ↗

4:12 PM ET 10-Q
Financial Results

Achieve Life Sciences Q3 2026 Results: Net Loss of $12.1M, Loss Narrows

Achieve Life Sciences significantly strengthened its liquidity position, ending September 30, 2026, with $201.5 million in cash and marketable securities compared to $36.4 million at the end of 2025. The company is focused on its NDA resubmission for cytisinicline following a CRL and is currently involved in arbitration with its supplier, Sopharma.

Key figure
Net loss $12.1M
4:04 PM ET 8-K
Financial Results

Achieve Life Sciences Financial Results

Achieve Life Sciences (rebranded as AchieveRx) reported third quarter 2026 financial results and provided a regulatory update on its smoking cessation drug, cytisinicline. The company remains on track to resubmit its New Drug Application (NDA) to the FDA in Q4 2026 and ended the period with $201.5 million in cash and equivalents.

Term
Q3 2026

“Becoming AchieveRx, The Quit Company, reflects our shift from a clinical-stage company to one preparing to launch what could be the first new FDA-approved prescription medicine in 20 years to help people who smoke quit.”

Andrew D. Goldberg, MD, Chief Executive Officer

“Our 52-week ORCA-OL results add to the growing body of evidence supporting cytisinicline as a potential treatment option for people looking to quit smoking. With an experienced launch team and our NDA resubmission on track for later this year, we are well positioned to bring cytisinicline to people who want to quit, if it is approved.”

Andrew D. Goldberg, MD, Chief Executive Officer
4:50 PM ET 8-K
Executive Compensation

Achieve Life Sciences Executive Compensation

Achieve Life Sciences appointed Benjamin Halladay as Chief Financial Officer, effective October 5, 2026. His compensation package includes a $525,000 base salary, a 40% target bonus, and equity awards consisting of 200,000 stock options and 200,000 restricted stock units. The agreement also provides for severance benefits ranging from 9 to 12 months of salary depending on the circumstances of termination.

Counterparty
Benjamin Halladay

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.